The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading
Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading
Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report
In a series of tweets, Swamy alleged that “Arvind Subramanian of Washington DC” had urged the US to act against India’s national interests, and called for him to be sacked. Source: The Indian Express | June 23, 2016 After having … Continue reading
India’s new intellectual property rights (IPR) policy attempts to address concerns of developed countries regarding India’s patent regime, while also protecting public interest, especially that of generic drug producers. However, through this effort of a balancing act, India might have … Continue reading
April 27, 2016 – The United States Trade Representative’s (USTR) 2016 “Special 301 Report” was released yesterday. Many countries – including India – are targeted and put on a ‘Priority Watch List’ for using legal tools to protect generic competition … Continue reading
By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.
BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading